Eloralintide ML
GMP ISO COA TDS 57 Inquiries
2883634-40-8
Pharmaceutical Grade
99.4%
香港
1g/5g/10g/50g/100g
2026-12-31
Semaglutide,Tirzepatide,Retatrutide,Cagrilintide,Amycretin,BI-456906
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Eloralintide (CAS No. 2883634-40-8) is a long-acting amylin analog and peptide-based pharmaceutical ingredient. Its modified peptide structure features a methylene thioacetal bridge and a C20 fatty diacid side chain, contributing to its distinctive molecular and physicochemical properties. As a peptide pharmaceutical raw material, Eloralintide is suitable for API research, analytical studies, and pharmaceutical development.
Certificates-
TDS
Basic Info-
Product Name:
Eloralintide
Other Name:Eloralintide;AMY1176;LY3841136;Eloralintide,LY3841136
CAS No.:2883634-40-8
Molecular Weight:0
EC Number:262-076-3
Color/Form:White to off-white
Categories:
Research-
Class:
Amylin receptor (AMYR) agonist (peptide, long-acting)
Status:Investigational — Phase 1/2 (T2DM and obesity)
Mechanism:Eloralintide is an amylin receptor agonist developed by Eli Lilly for type 2 diabetes and obesity. It activates the amylin receptor (AMYR), reducing food intake, delaying gastric emptying, and promoting satiety. It is structurally distinct from cagrilintide (Novo Nordisk). Being explored as monotherapy and in combination with GLP-1R agonists.
Activity note:Limited public data. Eloralintide is in early clinical development; specific EC50 values have not been publicly disclosed.
Source:MCE: Eloralintide (CAS 2883634-40-8); AbMole product data sheet.
References-
PubChem:Disclaimer:
Eloralintide is NOT FDA-approved or EMA-approved. It is in Phase 1/2 clinical development by Eli Lilly. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Semaglutide,Tirzepatide,Retatrutide,Cagrilintide,Amycretin,BI-456906
-
Location:
1603-1, C Building, Wanxia Center, Houhaibin Road, Nanshan, Shenzhen, China
-
Payment Terms:
100% TT in advance
-
Average lead Time:
14
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
201-300
-
Year of Establishment:
2025
"> -
-
Inquiry History57 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Eloralintide
1 KG May 28, 2026 
United Kingdom
Eloralintide
1 G Sep 1, 2026
United States
Eloralintide
1 MT Aug 31, 2026
United States
Eloralintide
1 G Aug 27, 2026 
Italy
Eloralintide
5 PCS Aug 19, 2026
United States
eloralintide
2 PCS Aug 2, 2026
United States
eloralintide
30 MG Jul 28, 2026
United States
Elora
32 G Jul 27, 2026
United States
Eloralintide
1 G Jul 13, 2026
United States
Eloralintide
10 PCS Jul 11, 2026 
Singapore
Eloralintide
1 G Jul 1, 2026
United States
eloralintide
50 MT Jun 12, 2026
United States
Eloralintide and Retatrutide
2 MT Jun 8, 2026
United States
Eloralintide
5 PCS May 27, 2026 
South Korea
eloralintide
2 G Feb 24, 2026
United States
Eloralintide
1 G Feb 20, 2026
United States
ELORALINTIDE
10 MG Feb 19, 2026
United States
Eloralintide
100 PCS Feb 15, 2026
United Kingdom
Eloralintide
10 Dec 28, 2025 
Germany
Eloralintide
200 MG Sep 1, 2026 Post an enquiry for this product